Mymetics Secures New Patent for Virosome based Vaccines
Epalinges, Switzerland, 29 November 2010
Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that the United States Patent and Trademark Office has issued a notice of allowance for the patent application "Phospholipid Virosome" # 10/544,939, based on WO 04/071492.
|Media Name||Media Type||Description||Download|
|Mymetics Secures New Patent for Virosome based Vaccines||Download|